Hamidreza Mohammadi | Neuropharmacology | Innovative Research Award

Published on by Top Pharmaceutical

Innovative Research Award

Hamidreza Mohammadi
Affiliation Mazandaran University of Medical science
Country Iran
Scopus ID 56962768300
Documents 1264
Citations 1370
h-index 24
Subject Area Neuropharmacology
Event International Top Pharmaceutical Awards
ORCID 0000-0002-7053-6850

Hamidreza Mohammadi is affiliated with Mazandaran University of Medical science, Iran, and has contributed to the fields of neuropharmacology, toxicology, oxidative stress research, mitochondrial dysfunction, and nanoparticle-mediated therapeutic development. His research profile reflects interdisciplinary investigations associated with pharmacological toxicology, mitochondrial protection, neuroprotective strategies, and oxidative injury mechanisms in experimental models.[1] His academic contributions include studies related to paraquat-induced neurotoxicity, nanoparticle therapeutics, oxidative stress biomarkers, and toxicological evaluation methodologies that are relevant to modern pharmaceutical and biomedical sciences.[2]

Abstract

The Innovative Research Award recognition highlights the scientific activities and academic contributions of Hamidreza Mohammadi in pharmaceutical toxicology and neuropharmacological sciences. His investigations include oxidative stress modulation, mitochondrial dysfunction analysis, paraquat-induced toxicity, nanoparticle-assisted therapeutic systems, and pharmacological interventions associated with cellular injury mechanisms. Published studies demonstrate collaborative research focused on toxicological pathways, mitochondrial protection, neuroprotective therapies, and nanomedicine-based pharmaceutical applications.[2] These scholarly activities have contributed to the advancement of experimental toxicology and translational pharmaceutical sciences in both preclinical and applied biomedical contexts.

Keywords

Neuropharmacology, Toxicology, Oxidative Stress, Mitochondrial Dysfunction, Paraquat Toxicity, Nanomedicine, Pharmaceutical Sciences, Experimental Pharmacology, Toxicological Research, Therapeutic Nanoparticles.

Introduction

Modern pharmaceutical sciences increasingly emphasize translational research approaches that integrate neuropharmacology, toxicology, nanotechnology, and mitochondrial medicine. Within this scientific environment, Hamidreza Mohammadi has participated in research investigating toxicant-induced cellular injury, neuroprotective mechanisms, oxidative stress pathways, and nanoparticle-assisted drug delivery systems. Several of his studies examine the biological consequences of paraquat exposure, mitochondrial dysfunction, and pharmacological interventions that may reduce oxidative injury in experimental models.[3] These investigations contribute to broader pharmaceutical discussions concerning therapeutic safety, oxidative balance, neurotoxicity prevention, and innovative biomedical strategies.

Research Profile

Hamidreza Mohammadi is associated with Mazandaran University of Medical Sciences and maintains an active academic profile in neuropharmacology and toxicological sciences.[1] His publication record includes collaborative investigations involving mitochondrial protection, toxicant-induced oxidative stress, neuroprotective therapeutics, nanoparticle systems, and pharmacological interventions targeting cellular dysfunction. His Scopus profile reports a substantial scholarly output and citation presence that reflects ongoing scientific engagement in pharmaceutical and biomedical research fields.[1]

Research Contributions

The scientific contributions of Hamidreza Mohammadi include studies focused on paraquat-induced neurotoxicity, oxidative mitochondrial injury, toxicological risk mechanisms, and nanoparticle-assisted therapeutic systems. Research publications have explored mitochondrial oxidative damage, antiemetic neuroprotection, toxicological evaluation of chemicals, and pharmacological mitigation of oxidative injury.[2] Additional work has examined the application of quercetin-loaded nanoparticles, curcumin formulations, and magnesium-based nanocarriers in experimental toxicology models.[4] These contributions collectively support scientific understanding of toxicant-induced physiological disruption and therapeutic intervention strategies.

Publications

Selected publications associated with Hamidreza Mohammadi include research articles in journals related to toxicology, pharmaceutical sciences, oxidative stress biology, and neuropharmacology. His studies investigate paraquat toxicity, mitochondrial dysfunction, nanoparticle therapeutics, and toxicological pharmacology using experimental models and translational biomedical approaches.[2]

Research Impact

The research activities of Hamidreza Mohammadi demonstrate interdisciplinary relevance across pharmaceutical toxicology, neuropharmacology, nanomedicine, and mitochondrial biology. His scholarly output contributes to scientific understanding of oxidative stress-mediated toxicity and therapeutic mitigation strategies. Research findings associated with nanoparticle formulations, mitochondrial protection, and toxicological pharmacology may support future investigations into safer pharmaceutical interventions and experimental therapeutic systems.[5] Citation metrics and publication activity further indicate continued engagement with internationally indexed pharmaceutical research platforms.

Award Suitability

The Innovative Research Award category is aligned with scholarly activities involving emerging pharmaceutical methodologies, toxicological innovation, and interdisciplinary biomedical research. Hamidreza Mohammadi’s work in oxidative stress mechanisms, neuroprotective pharmacology, toxicological assessment, and nanoparticle-based therapeutics reflects research themes commonly associated with contemporary pharmaceutical innovation.[3] His contributions demonstrate relevance to translational pharmaceutical sciences and experimental therapeutic development within academic and biomedical research communities.

Conclusion

Hamidreza Mohammadi has contributed to pharmaceutical and biomedical sciences through research activities centered on neuropharmacology, toxicology, oxidative stress, mitochondrial dysfunction, and nanomedicine. His publication profile reflects continued academic engagement in experimental toxicology and therapeutic investigation. The Innovative Research Award recognition acknowledges these scholarly contributions and their relevance to advancing pharmaceutical research methodologies and translational biomedical understanding.

References

  1. Elsevier. (n.d.). Scopus author details: Hamidreza Mohammadi, Author ID 56962768300. Scopus.https://www.scopus.com/authid/detail.uri?authorId=56962768300
  2. Jahani, R., Pourbahram, P., Seyedabadi, M., Nasiri, F., & Mohammadi, H. (2025). The role of GABAergic receptors in acute, subacute, and withdrawal syndrome on pain and seizure thresholds in mice: A connection to mitochondrial function and oxidative stress in the brain. Toxicology Reports.DOI: https://pubmed.ncbi.nlm.nih.gov/41312119/
  3. Sadeghi, S., Karami, M., Madanchi, H., Yazdian-Robati, R., Seyedabadi, M., Ghasempouri, S. K., Siahposht-Khachaki, A., & Mohammadi, H. (2025). Microfluidic techniques in the development of PLGA nanoparticles: a tri-combination therapy for paraquat-induced cytotoxicity. Toxicology Research.DOI: https://doi.org/10.1093/toxres/tfaf133
  4. Khederzadeh, A., Ebrahimnejad, P., Seyedabadi, M., Babaei, A., Talebpour Amiri, F., Aslani, N., Mojarad-Jabali, S., & Mohammadi, H. (2024). Synergistic effect of curcumin and Piperine loaded Niosomal nanoparticles on acute pulmonary toxicity induced by Paraquat in mice. Toxicology Research.DOI: https://doi.org/10.1093/toxres/tfae181
  5. Ashari, S., Karami, M., Shokrzadeh, M., Bagheri, A., Ghandadi, M., Ranaee, M., Dashti, A., & Mohammadi, H. (2022). Quercetin ameliorates Di (2-ethylhexyl) phthalate-induced nephrotoxicity by inhibiting NF-κB signaling pathway. Toxicology Research.DOI: https://doi.org/10.1093/toxres/tfac006

Mahnaz Bayat | Neuropharmacology | Research Excellence Award

Published on by Top Pharmaceutical

Dr. Mahnaz Bayat | Neuropharmacology | Research Excellence Award

clinical neurology research center | Iran

Dr. Mahnaz Bayat is a dedicated and research-driven academic with extensive expertise spanning both experimental and clinical dimensions of neurological disorders. She currently serves as an Assistant Professor at the Clinical Neurology Research Center, where her work integrates translational neuroscience with patient-oriented clinical research. Dr. Bayat has substantial hands-on experience in clinical trials and advanced neurological investigations, with a particular emphasis on bridging laboratory discoveries and clinical application. Her scientific expertise includes disease modeling across a broad spectrum of neurological conditions, as well as sophisticated electrophysiological recording techniques that enable in-depth analysis of neural function and dysfunction. In parallel with her research activities, she is deeply engaged in graduate and postgraduate education, serving as a thesis advisor for neurology residents and supervising multiple Master’s and doctoral students in the basic medical sciences. Her academic teaching portfolio encompasses physiology education for students across medicine, dentistry, and pharmacy, reflecting her strong interdisciplinary foundation. Dr. Bayat has established a solid publication record in peer-reviewed scientific journals and is recognized for her meaningful contributions to collaborative and interdisciplinary research initiatives. Her primary research interests include electrophysiology, clinical neurology, neurodegenerative diseases, neurological biomarkers, and translational neuroscience, with a growing focus on improving diagnostic precision and therapeutic strategies. Through her combined roles as a clinician-scientist, educator, and researcher, Dr. Bayat continues to advance neurological science while contributing to the development of future clinicians and researchers in the field.

Citation Metrics (Scopus)

600

450

300

150

0

Citations
581

Documents
50

h-index
15

Citations
Documents
h-index


View Scopus Profile View Google Scholar Profile

Featured Publications

Slawomir Michalak | Neuropharmacology | Top Pharmaceutical Breakthrough Award

Published on by Top Pharmaceutical

Prof. Slawomir Michalak | Neuropharmacology | Top Pharmaceutical Breakthrough Award

Institute of Neurological Disorders Poznan University of Medical Sciences | Poland

Prof. Slawomir Michalak is an accomplished neurologist, neuropathologist, and laboratory medicine specialist whose contributions have significantly advanced clinical neuroscience, translational neurology, and biomarker-driven research. He leads the Stroke Unit at the University Hospital in Poznań while simultaneously heading the Department of Neurology, the Department of Neurosurgery, and the Institute of Neurological Disorders at Poznan University of Medical Sciences. His academic journey includes prestigious international fellowships at the Biochemisches Institut of Christian Albrechts Universität in Kiel and at the Istituto di Patologia Generale of the Università degli Studi in Perugia, where he strengthened his foundation in molecular neuropathology. He further enhanced his expertise through intensive neuropathology and laboratory medicine courses in leading European scientific hubs such as Berlin, Budapest, Lübeck, Aachen, and specialized mitochondrial research programs in Schroecken, Austria. As a visiting professor at the M. Ospanov West Kazakhstan State Medical Academy, he delivered advanced lectures and supervised doctoral research in neurodegenerative and demyelinating disorders.Prof. Michalak’s scientific portfolio demonstrates exceptional breadth and innovation. He has played a central role in multidisciplinary research initiatives, including a large Polish–Singaporean project developing computer-aided decision support systems for acute ischemic stroke therapy, and joint studies with international collaborators aimed at profiling pathological proteins in skin biopsies of patients with movement disorders. His work also encompasses biochemical and clinical signature identification for interferon therapy response in multiple sclerosis. As a contributor to the European COST Action project on mitochondrial mapping, he has examined the complex interplay of evolution, age, gender, lifestyle, and environmental factors on mitochondrial dynamics. His ongoing clinical research includes a major investigation on the influence of Cerebrolysin on blood–brain barrier integrity in acute ischemic stroke. He also collaborates with global experts on smart digital therapeutics using generative artificial intelligence and contributes to the Glioblastoma Research Group at Poznan University of Medical Sciences to advance biomarker-based early detection strategies.With more than five hundred scientific publications, a substantial cumulative impact factor, over two thousand citations, and a strong h-index, Prof. Michalak has established himself as a leading figure in contemporary neurology. His book publications, extensive consultancy roles, and active involvement in translational industry–academia partnerships further highlight his enduring impact. His research in stroke biology, neuroimmunology, neuro-oncology, and molecular biomarkers continues to shape clinical understanding and inspire innovation across the global neuroscience community.

Profile: Google Scholar

Featured Publications

Ambrosius, W., Michalak, S., & Kozubski, W., & Kalinowska, A. (n.d.). Myelin oligodendrocyte glycoprotein antibody-associated disease: Current insights into the disease pathophysiology, diagnosis and management. International Journal of Molecular Sciences, 22(1), 100.

Kazmierski, N. W. R., Michalak, S., & Wencel-Warot, A. (n.d.). Serum tight-junction proteins predict hemorrhagic transformation in ischemic stroke patients. Neurology, 79, 160.

Jasiak-Zatonska, M., Kalinowska-Łyszczarz, A., Michalak, S., & Kozubski, W. (n.d.). The immunology of neuromyelitis optica—Current knowledge, clinical implications, controversies and future perspectives. International Journal of Molecular Sciences, 17(3), 273.

Wyciszkiewicz, A., Kalinowska-Łyszczarz, A., Nowakowski, B., Kaźmierczak, K., & Michalak, S. (n.d.). Expression of small heat shock proteins in exosomes from patients with gynecologic cancers. Scientific Reports, 9(1), 9817.

Zaborowski, M. S., Spaczynski, M., & Nowak-Markwitz, E., & Michalak, S. (n.d.). Paraneoplastic neurological syndromes associated with ovarian tumors. Journal of Cancer Research and Clinical Oncology, 71.

Adamczak-Ratajczak, A., Kupsz, J., Owecki, M., Zielonka, D., Sowinska, A., & Michalak, S., et al. (n.d.). Circadian rhythms of melatonin and cortisol in manifest Huntington’s disease and in acute cortical ischemic stroke. Journal of Physiology and Pharmacology, 68(4), 539–546.

M. Imad Damaj | Neuropharmacology | Best Researcher Award

Published on by Top Pharmaceutical

M. Imad Damaj | Neuropharmacology | Best Researcher Award

Prof. Dr. M. Imad Damaj, Virginia Commonwealth University, United States

Prof. Dr. M. Imad Damaj is a distinguished pharmacologist specializing in pain, neuropathy, and drug dependence. A professor at Virginia Commonwealth University (VCU), he co-directs the Translational Research Initiative for Pain and Neuropathy. Holding a Ph.D. in Pharmacology from the University of Paris XI, he has made significant contributions to neuropharmacology and drug addiction research. An award-winning educator, he has received the VCU Award of Excellence and is a National Academy of Inventors inductee. His extensive work includes NIH study sections, journal editorial roles, and mentoring future scientists. 🌍📚🔬

Publication Profile

Scopus

Education

Prof. Dr. M. Imad Damaj 🎓 began his academic journey with a B.S. in Pharmacy from the University of St-Joseph (French Faculty of Medicine) in Beirut, Lebanon, in 1985. He then pursued an M.S. in Hospital Pharmacy (DESS) at the School of Pharmacy, University of Paris VI, France, in 1986. His passion for pharmacology led him to earn a Ph.D. in 1991 from the University of Paris XI, under the mentorship of Dr. Christian Jacquot. 🧪 His dissertation focused on the pharmacological and pharmacokinetic evaluation of COR3224, a novel antidepressant agent, in rats, contributing valuable insights to the field. 🧬

Experience 

Prof. Dr. M. Imad Damaj 🧪 has an extensive background in training and research. He began as a Hospital Pharmacist at the Pediatric Parenteral Nutrition Unit, Necker Pediatric Hospital, Paris (1985-1986) and later became a Pharmacy Resident at Ste-Anne Neuropsychiatric Hospital (1986-1987). His academic journey included a predoctoral fellowship at the University of Paris XI (1987-1991) and a postdoctoral fellowship at the Medical College of Virginia (1991-1993). 🎓 Since 1994, he has been actively involved in teaching at Virginia Commonwealth University, covering pharmacology, drug dependence, and pain control, mentoring students in pharmacy, dentistry, and medical sciences.

Awards

Prof. Dr. M. Imad Damaj 🎓 has received numerous prestigious awards and honors throughout his career. In 1990, he earned the SARGET Laboratories Award for his research on antidepressants in rat brains. He received postdoctoral travel awards from ASPET (1992) and CPDD (1993). Recognized as an Outstanding Young Investigator in 1995, he continued to receive accolades, including multiple NIDA Travel Awards (1996, 1999) and the College de France Award (2001). 🌟 At VCU, he was named Professor of the Year (2014) and won multiple teaching awards. In 2023, he was inducted into the National Academy of Inventors. 🏅

Professional Activity

Prof. Dr. M. Imad Damaj 🧪 has been actively engaged in professional activities, serving as an ad hoc reviewer for esteemed journals such as Journal of Pharmacology and Experimental Therapeutics, British Journal of Pharmacology, and Neurochemistry International. Since 1993, he has contributed as a judge for the Virginia Junior Academy of Sciences and Virginia Academy of Sciences. 🎓 He has also participated in educational outreach, including the Mini-Med School of Virginia. From 2002-2018, he was on the Editorial Advisory Board for JPET, and in 2021, he became Associate Editor for Frontiers in Pain Research.

Research Focus

Prof. Dr. Mohamad Imad Damaj is a distinguished researcher in neuropharmacology 🧠💊, with a strong focus on nicotinic acetylcholine receptors (nAChRs) 🔬 and their role in addiction, pain, and neuropsychiatric disorders. His work explores the mechanisms of nicotine addiction 🚬, opioid withdrawal ⚠️, and neuropathic pain 🔥, employing advanced mouse models 🐭 to investigate behavioral and molecular responses. He has contributed significantly to understanding novel pharmacological interventions 💉, including PPARα agonists and α7 nicotinic receptor modulators. His research has broad implications for pain management, substance use disorders, and neuroprotection.

Publication Top Notes

Characterization of a novel oronasal-restricted nicotine vaping self-administration model in mice

New PPARα Agonist A190-Loaded Microemulsion for Chemotherapy-Induced Peripheral Neuropathy

Sulfonium Moieties as Ammonium Bioisosteres: Novel Ligands for the Alpha7 Nicotinic Acetylcholine Receptor

Identification of ethanol analgesia quantitative trait loci and candidate genes in BXD recombinant inbred mouse lines

Upregulation of the neuropeptide receptor calcitonin receptor-like in the spinal cord via MLL2 in a mouse model of paclitaxel-induced peripheral neuropathy

Voluntary nicotine consumption and reward in a subset of diversity outbred founder strains

Activation of α7 nicotinic receptors attenuated hyperalgesia and anxiety induced by palatable obesogenic diet withdrawal

Proteomic analysis of dorsal root ganglia in a mouse model of paclitaxel-induced neuropathic pain

Characterization and validation of a spontaneous acute and protracted oxycodone withdrawal model in male and female mice

The potential effect of α7 nicotinic receptors modulation on palatable food-induced dependence-like behaviors